AR077931A2 - Anticuerpos contra la interleuquina-13 humana y usos de los mismos - Google Patents
Anticuerpos contra la interleuquina-13 humana y usos de los mismosInfo
- Publication number
- AR077931A2 AR077931A2 ARP100103010A ARP100103010A AR077931A2 AR 077931 A2 AR077931 A2 AR 077931A2 AR P100103010 A ARP100103010 A AR P100103010A AR P100103010 A ARP100103010 A AR P100103010A AR 077931 A2 AR077931 A2 AR 077931A2
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- light chain
- cdr3
- domain
- sequence
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 abstract 7
- 102000018358 immunoglobulin Human genes 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 6
- 108020004707 nucleic acids Proteins 0.000 abstract 6
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 102000003816 Interleukin-13 Human genes 0.000 abstract 5
- 108090000176 Interleukin-13 Proteins 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 230000000295 complement effect Effects 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000244186 Ascaris Species 0.000 abstract 1
- 206010006482 Bronchospasm Diseases 0.000 abstract 1
- 208000000059 Dyspnea Diseases 0.000 abstract 1
- 206010013975 Dyspnoeas Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241001494479 Pecora Species 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000007885 bronchoconstriction Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000019207 human interleukin-13 Human genes 0.000 abstract 1
- 230000009610 hypersensitivity Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000003843 mucus production Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 208000013220 shortness of breath Diseases 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se posee además una composicion farmacéutica que comprende el anticuerpo divulgado; una célula huésped; un método para proporcionar un anticuerpo recombinante; un método para tratar un trastorno asociado con la IL-13. Reivindicacion 1: Un anticuerpo o un fragmento del mismo de union al antígeno, que se une a la IL-13 con un KD de menos de 5 x 10-7 M y que tiene una o más de las propiedades siguientes: (a) la secuencia variable del dominio de inmunoglobulina de cadena pesada comprende una CDR3 pesada de mAb13.2 (SEQ ID Ns 24), o una CDR3 que difiere por menos de 3 sustituciones de aminoácidos de una CDR3 correspondiente de mAb13.2; (b) la secuencia variable de dominio de inmunoglobulina de cadena liviana comprende una CDR3 de cadena liviana de mAb13.2 (SEO ID Ns 21), o una CDR3 que difiere por menos de 3 sustituciones de aminoácidos de una CDR3 correspondiente de mAb13.2; (c) la secuencia variable de dominio de inmunoglobulina de cadena pesada comprende una secuencia codificada por un ácido nucleico que hibridiza bajo condiciones muy rigurosas hasta el complemento de un ácido nucleico que codifica un dominio variable de cadena pesada de h13.2 (SEQ ID Ns 11, 12 o 35); (d) la secuencia variable de dominio de inmunoglobulina de cadena liviana comprende una secuencia codificada por un ácido nucleico que hibridiza bajo condiciones muy rigurosas hasta el complemento de un ácido nucleico que codifica un dominio variable de cadena liviana de h13.2 (SEQ ID Ns 15, 16 o 36); (e) la secuencia variable de dominio de inmunoglobulina de cadena pesada es por lo menos 90% idéntica a un dominio variable de cadena pesada de h13.2 (SEQ ID Ns 11, 12 o 35); (f) la secuencia variable de dominio de inmunoglobulina de cadena liviana es por lo menos 90% idéntica a un dominio variable de cadena liviana de h13.2 (SEQ ID Ns 15, 16 o 36); (g) la proteína compite con mAb13.2 para unirse a la IL-13 humana; (h) la proteína entra en contacto con uno o más aminoácidos de IL-13 seleccionados a partir del grupo que consiste en 68, 72, 88, 91, 92, 93, y 105 de la SEQ ID Ns 31; (i) la secuencia de dominio variable de cadena pesada tiene la misma estructura canonica que mAb13.2; (j) la secuencia variable de dominio de cadena liviana tiene la misma estructura canonica que mAb13.2; y (k) confiere un efecto protector posterior a la inyeccion contra la exposicion al antígeno de Ascaris en un modelo de oveja por lo menos 6 semanas después de la inyeccion. Reivindicacion 18: Un ácido nucleico que comprende una secuencia que (i) codifica un polipéptido que comprende una secuencia variable de dominio de inmunoglobulina de cadena liviana que: (a) comprende a una CDR3 de cadena liviana de mAb13.2 (SEQ ID Ns 21), o una CDR3 que difiere por menos en 3 sustituciones de aminoácidos de una CDR3 correspondiente de mAb13.2; o (b) es por lo menos 90% idéntica a un dominio variable de cadena liviana de h13.2 (SEQ ID Ns 15, 16 o 36); o (ii) hibridiza bajo condiciones muy rigurosas al complemento de un ácido nucleico que codifica un dominio variable de cadena pesada de h13.2 (SEQ ID Ns 15, 16 o 36). Reivindicacion 45: Un método para tratar a un paciente que presenta un síntoma de asma seleccionado a partir del grupo que consiste en respiracion dificultosa, falta de aliento, broncoconstriccion, hipersensibilidad de las vías aéreas, disminucion de la capacidad pulmonar, fibrosis, inflamacion de las vías aéreas, y produccion de moco, dicho método comprende el paso de administrar al paciente un anticuerpo que se une a la IL-13 e interfiere con la formacion de un complejo funcional de senalizacion de la IL-13.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57847304P | 2004-06-09 | 2004-06-09 | |
| US57873604P | 2004-06-09 | 2004-06-09 | |
| US58137504P | 2004-06-22 | 2004-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077931A2 true AR077931A2 (es) | 2011-10-05 |
Family
ID=35503715
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102343A AR049390A1 (es) | 2004-06-09 | 2005-06-08 | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| ARP100103010A AR077931A2 (es) | 2004-06-09 | 2010-08-17 | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102343A AR049390A1 (es) | 2004-06-09 | 2005-06-08 | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7615213B2 (es) |
| EP (3) | EP1756161A2 (es) |
| JP (4) | JP2008515776A (es) |
| KR (3) | KR101462878B1 (es) |
| CN (2) | CN101141980B (es) |
| AR (2) | AR049390A1 (es) |
| AU (2) | AU2005252700A1 (es) |
| BR (2) | BRPI0510881A (es) |
| CA (2) | CA2567081A1 (es) |
| CR (2) | CR8784A (es) |
| EC (2) | ECSP067072A (es) |
| IL (2) | IL179093A0 (es) |
| MX (2) | MXPA06014299A (es) |
| NO (2) | NO20070087L (es) |
| NZ (1) | NZ582046A (es) |
| RU (2) | RU2427589C2 (es) |
| SG (2) | SG155260A1 (es) |
| TW (1) | TWI391133B (es) |
| WO (2) | WO2005121177A2 (es) |
Families Citing this family (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| SI2805728T1 (sl) | 2003-12-23 | 2020-07-31 | Genentech, Inc. | Nova protitelesa proti il 13 in uporabe le-teh |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| WO2006055638A2 (en) | 2004-11-17 | 2006-05-26 | Abgenix, Inc. | Fully human monoclonal antibodies to il-13 |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| US9072716B2 (en) | 2005-04-15 | 2015-07-07 | The United States of America, as represented by the Secretary Department of Health by Human Servies | Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells |
| SI1942939T2 (sl) | 2005-09-30 | 2021-11-30 | Medimmune Limited | Sestavek protitelesa proti interlevkinu-13 |
| US20070237763A1 (en) * | 2005-10-06 | 2007-10-11 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
| US20070202106A1 (en) * | 2005-10-06 | 2007-08-30 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
| PT2532679T (pt) * | 2005-10-21 | 2017-07-18 | Novartis Ag | Anticorpos humanos contra il13 e utilizações terapêuticas |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| CN101378782A (zh) | 2005-12-21 | 2009-03-04 | 惠氏公司 | 粘度降低的蛋白质制剂及其用途 |
| CA2636854A1 (en) * | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind il-4 and/or il-13 |
| SG170750A1 (en) | 2006-03-17 | 2011-05-30 | Biogen Idec Inc | Stabilized polypeptide compositions |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| EP4001409A1 (en) * | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CA2656379A1 (en) * | 2006-06-21 | 2007-12-27 | Apogenix Gmbh | Differential cytokine expression in human cancer |
| WO2008003514A2 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
| SI3339445T1 (sl) * | 2006-09-08 | 2020-12-31 | Abbvie Bahamas Ltd. | Beljakovine za vezavo interlevkin-13 |
| ES2764222T3 (es) * | 2006-09-08 | 2020-06-02 | Wyeth Llc | Lavado con arginina en la purificación de proteínas mediante el uso de cromatografía de afinidad |
| US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| KR20090069330A (ko) * | 2006-10-12 | 2009-06-30 | 와이어쓰 | 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화 |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| WO2008057240A2 (en) | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
| CA2672215A1 (en) * | 2006-12-11 | 2008-06-19 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| MX2009007406A (es) * | 2007-01-09 | 2010-01-25 | Wyeth Corp | Formulaciones de anticuerpo anti-il-13 y usos de las mismas. |
| MX2009007570A (es) | 2007-01-16 | 2009-07-22 | Abbott Lab | Metodos para tratar la psoriasis. |
| SI2059534T1 (sl) | 2007-02-23 | 2012-08-31 | Schering Corp | Umetno proizvedena anti-il-23p19 antitelesa |
| CN101663320A (zh) | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
| CA2681752A1 (en) | 2007-03-29 | 2008-10-09 | Abbott Laboratories | Crystalline anti-human 1l-12 antibodies |
| RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
| US7890055B1 (en) * | 2007-07-09 | 2011-02-15 | Everlokt Corporation | Touch field compound field detector personal ID |
| RU2010107994A (ru) | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| PE20090711A1 (es) | 2007-09-26 | 2009-07-15 | Chugai Pharmaceutical Co Ltd | Region constante de anticuerpo mutante |
| EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| JP2009106163A (ja) * | 2007-10-26 | 2009-05-21 | Kyushu Univ | 核酸配列、ベクター、形質転換体、製造方法、及び、核酸配列プライマー |
| ES2614284T3 (es) * | 2007-11-30 | 2017-05-30 | Glaxo Group Limited | Construcciones de unión a antígenos |
| JP5682995B2 (ja) | 2007-12-05 | 2015-03-11 | 中外製薬株式会社 | 抗ｎｒ１０抗体、およびその利用 |
| KR20100126515A (ko) | 2008-03-18 | 2010-12-01 | 아보트 러보러터리즈 | 건선의 치료방법 |
| EP2310049A4 (en) | 2008-07-08 | 2013-06-26 | Abbvie Inc | PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF |
| KR20110043786A (ko) | 2008-08-20 | 2011-04-27 | 센토코 오르토 바이오테크 인코포레이티드 | 조작된 항-ｉｌ-13 항체, 조성물, 방법 및 용도 |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CN102272161A (zh) * | 2008-11-06 | 2011-12-07 | 阿雷克森制药公司 | 免疫原性降低的工程抗体与制备方法 |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
| JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
| JP5669732B2 (ja) | 2009-05-15 | 2015-02-12 | 中外製薬株式会社 | 抗ａｘｌ抗体 |
| US20120177668A1 (en) * | 2009-07-06 | 2012-07-12 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
| WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
| SI3037104T1 (sl) | 2009-10-20 | 2020-10-30 | Abbvie Inc. | Izolacija in prečiščevanje protiteles anti-IL-13 z uporabo afinitetne kromatografije beljakovine A |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| KR20180053775A (ko) | 2010-04-23 | 2018-05-23 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| KR102099580B1 (ko) | 2010-11-17 | 2020-04-10 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| RU2578468C2 (ru) | 2010-12-16 | 2016-03-27 | Дженентек, Инк. | Способы диагностики и лечения, связанные с ингибированием th2 |
| BR112013019499B1 (pt) | 2011-02-04 | 2023-01-10 | Genentech, Inc. | Proteína heteromultimérica variante ou anticorpo igg modificado, método para produzir uma proteína heteromultimérica variante ou anticorpo igg modificado, composição, método para preparar uma proteína heteromultimérica e proteína heteromultimérica variante |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| KR20230005405A (ko) | 2011-02-25 | 2023-01-09 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체 |
| JP2014510730A (ja) | 2011-03-16 | 2014-05-01 | サノフイ | デュアルｖ領域抗体様タンパク質の使用 |
| SG10201505454SA (en) | 2011-07-13 | 2015-09-29 | Abbvie Inc | Methods and compositions for treating asthma using anti-il-13 antibodies |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
| KR101521224B1 (ko) | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
| EP2948134B1 (en) | 2013-01-24 | 2020-03-04 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mtor inhibitors |
| EP2981286A4 (en) * | 2013-04-05 | 2016-08-24 | Hoffmann La Roche | ANTI-IL-4 ANTIBODIES AND BISPECIFIC ANTIBODIES AND USES THEREOF |
| CA2921999C (en) | 2013-09-13 | 2023-03-21 | Genentech, Inc. | Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2 |
| EP3044323B1 (en) | 2013-09-13 | 2022-04-06 | F. Hoffmann-La Roche AG | Methods for detecting and quantifying host cell protein in cell lines |
| WO2015046467A1 (ja) | 2013-09-27 | 2015-04-02 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| MX2016005159A (es) | 2013-10-23 | 2016-07-05 | Genentech Inc | Metodos de diagnostico y tratamiento de trastornos eosinofilicos. |
| MX2016010729A (es) | 2014-02-21 | 2016-10-26 | Genentech Inc | Anticuerpos biespecificos anti-il-13 / il-17 y sus usos. |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| CR20170251A (es) | 2014-12-19 | 2017-07-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| CA2963760A1 (en) | 2014-12-19 | 2016-06-23 | Yoshinao Ruike | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| JP2018510842A (ja) | 2015-02-05 | 2018-04-19 | 中外製薬株式会社 | イオン濃度依存的抗原結合ドメインを含む抗体、Ｆｃ領域改変体、ＩＬ−８に結合する抗体、およびその使用 |
| WO2016136933A1 (ja) | 2015-02-27 | 2016-09-01 | 中外製薬株式会社 | Ｉｌ－６関連疾患治療用組成物 |
| AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
| AR103935A1 (es) | 2015-03-16 | 2017-06-14 | Genentech Inc | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2 |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
| BR112018068363A2 (pt) | 2016-03-14 | 2019-01-15 | Chugai Pharmaceutical Co Ltd | fármaco terapêutico indutor de dano celular para uso em terapia de câncer |
| EP3448391B1 (en) | 2016-04-27 | 2024-05-29 | AbbVie Manufacturing Management Unlimited Company | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
| RS64550B1 (sr) | 2016-09-23 | 2023-09-29 | Hoffmann La Roche | Upotreba il-13 antagonista za lečenje atopičnog dermatitisa |
| WO2018098370A1 (en) | 2016-11-23 | 2018-05-31 | Immunoah Therapeutics, Inc. | 4-1bb binding proteins and uses thereof |
| KR20190091325A (ko) | 2016-12-07 | 2019-08-05 | 프로제너티, 인크. | 위장관 검출 방법, 디바이스 및 시스템 |
| IL302385B2 (en) | 2017-01-06 | 2024-06-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| MX2019013072A (es) | 2017-05-02 | 2019-12-16 | Merck Sharp & Dohme | Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. |
| CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理（江苏）有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
| CA3226165A1 (en) | 2018-02-09 | 2019-08-15 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
| GB201802487D0 (en) * | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
| MX2020009639A (es) | 2018-03-16 | 2021-01-08 | Zoetis Services Llc | Vacunas de peptídos contra interleucina-31. |
| EP3765500A2 (en) | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Interleukin-31 monoclonal antibodies for veterinary use |
| WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
| WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
| IL283268B1 (en) | 2018-11-19 | 2024-05-01 | Biora Therapeutics Inc | Methods and devices for treating the disease with hyperpoietic substances |
| WO2020191346A1 (en) | 2019-03-21 | 2020-09-24 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| JP2022528324A (ja) * | 2019-03-26 | 2022-06-10 | アスラン ファーマシューティカルズ ピーティーイー リミテッド | 抗ｉｌ１３ｒ抗体またはその結合フラグメントを用いた治療 |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| CN114605535A (zh) * | 2020-12-08 | 2022-06-10 | 深圳福沃药业有限公司 | 抗il-13抗体及其用途 |
| WO2022197782A1 (en) | 2021-03-17 | 2022-09-22 | Receptos Llc | Methods of treating atopic dermatitis with anti il-13 antibodies |
| CN118076636A (zh) | 2021-09-15 | 2024-05-24 | 德米拉公司 | Il-13抑制剂用于治疗结节性痒疹 |
| CA3235096A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0307434B2 (en) * | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
| US5359037A (en) * | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
| WO1990005183A1 (en) * | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5011778A (en) * | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
| CA2071908C (en) | 1989-12-20 | 2002-04-30 | Lata Ramanathan | Antibody antagonists of human interleukin-4 |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5246701A (en) * | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
| ES2054601T3 (es) * | 1991-03-29 | 1996-04-01 | Sanofi Sa | Proteina con actividad de tipo citoquina, adn recombinante codante para esta proteina, celulas y microorganismos transformados. |
| LU91067I2 (fr) * | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
| AU3658093A (en) | 1992-02-10 | 1993-09-03 | Seragen, Inc. | Desensitization to specific allergens |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| WO1994004680A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Human interleukin-13 |
| US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
| EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
| JP3007977B2 (ja) * | 1993-09-02 | 2000-02-14 | トラスティーズ・オブ・ダートマス・カレッジ | 抗原特異的なｔ細胞寛容の誘導方法 |
| US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
| GB9415379D0 (en) * | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
| US5696234A (en) * | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
| US5705154A (en) * | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
| US20010053371A1 (en) | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
| DE69638050D1 (de) | 1995-10-23 | 2009-11-19 | Zenyth Operations Pty Ltd | Hemopoietin-rezeptor und dafür kodierende genetische sequenzen |
| US6911530B1 (en) * | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
| FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
| DE69721548T2 (de) | 1996-02-09 | 2004-04-01 | Abbott Laboratories(Bermuda)Ltd. | HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN |
| US5710023A (en) * | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
| US6664227B1 (en) * | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
| US7078494B1 (en) * | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
| WO1997033913A1 (en) | 1996-03-13 | 1997-09-18 | Zymogenetics, Inc. | Cytokine-receptor expressed in testis cells |
| EP0812913A3 (en) | 1996-06-12 | 1999-08-04 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
| WO1997047741A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
| AU6450196A (en) | 1996-06-12 | 1998-01-07 | Human Genome Sciences, Inc. | Hr-1 receptor |
| WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
| GB9625899D0 (en) * | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
| HUP0000833A3 (en) | 1997-01-10 | 2001-09-28 | Biogen Idec Ma Inc Cambridge | Treatment of lupus nephritis with anti-cd40l compounds |
| US6387615B2 (en) * | 1997-04-11 | 2002-05-14 | Isis Innovation Limited | Methods and materials for the diagnosis or prognosis of asthma |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9723553D0 (en) * | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| US6576232B1 (en) * | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
| US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| CA2356779C (en) | 1998-12-14 | 2012-03-13 | Genetics Institute, Inc. | Cytokine receptor chain |
| US7553487B2 (en) * | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CN1230421C (zh) | 1999-02-10 | 2005-12-07 | 三菱制药株式会社 | 酰胺化合物及其药物用途 |
| AU5756100A (en) | 1999-06-21 | 2001-01-09 | Genetics Institute Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
| WO2001023410A2 (en) | 1999-09-28 | 2001-04-05 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the interleukin 13 gene |
| EP1222212A4 (en) | 1999-10-06 | 2005-05-04 | Penn State Res Found | MUTANTS OF IL-13 |
| GB0004016D0 (en) * | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
| US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
| WO2001077332A2 (en) * | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| AU2001272925A1 (en) | 2000-05-26 | 2001-12-11 | Immunex Corporation | Use of interleukin-4 antagonists and compositions thereof |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| ES2311558T3 (es) | 2000-10-20 | 2009-02-16 | Genetics Institute, Inc. | Uso de inhibidores de la il-13 para el tratamiento de tumores. |
| CA2433353C (en) * | 2000-12-28 | 2017-03-21 | Altus Biologics, Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| US6649935B2 (en) | 2001-02-28 | 2003-11-18 | International Business Machines Corporation | Self-aligned, planarized thin-film transistors, devices employing the same |
| GB0105360D0 (en) * | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
| US7216242B2 (en) * | 2001-03-16 | 2007-05-08 | Dualcor Technologies, Inc. | Personal electronics device with appliance drive features |
| AUPR544401A0 (en) * | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
| IL159215A0 (en) * | 2001-06-07 | 2004-06-01 | Wyeth Corp | A solution of interleukin-13 and methods utilizing the same |
| US7321026B2 (en) * | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US20030023555A1 (en) * | 2001-07-26 | 2003-01-30 | Cashworks, Inc. | Method and system for providing financial services |
| CA2842429A1 (en) | 2001-10-19 | 2003-05-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
| CA2464695A1 (en) * | 2001-10-26 | 2003-05-01 | Centocor, Inc. | Il-13 mutein proteins, antibodies, compositions, methods and uses |
| US20040248260A1 (en) * | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
| US20040234499A1 (en) * | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| JPWO2003046009A1 (ja) * | 2001-11-27 | 2005-04-07 | 持田製薬株式会社 | 抗ＩＬ１３レセプターα１中和抗体 |
| US7541040B2 (en) * | 2001-12-04 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Serivces | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
| EP1325868A1 (en) | 2002-01-08 | 2003-07-09 | Tetra Laval Holdings & Finance SA | Packaging unit for continuously producing sealed packages, containing pourable food products, from a tube of packaging material |
| EP1576013A4 (en) * | 2002-03-22 | 2008-08-13 | Amrad Operations Pty Ltd | MONOCLONAL ANTIBODY AGAINST THE INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RA1) |
| AU2003223497A1 (en) * | 2002-04-05 | 2003-10-27 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
| US6811780B2 (en) * | 2002-05-01 | 2004-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat HIV infection and AIDS |
| NZ537726A (en) | 2002-06-14 | 2008-06-30 | Brigham & Womens Hospital | Methods of treating and preventing colitis involving IL-13 and NK-T cells |
| JP2004121218A (ja) * | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
| WO2004019979A2 (en) * | 2002-08-30 | 2004-03-11 | Glaxo Group Limited | Vaccine comprising il-13 and an adjuvant |
| EP2322201A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| JP2011516026A (ja) | 2002-11-26 | 2011-05-26 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| CN100434440C (zh) | 2002-12-02 | 2008-11-19 | 阿布格尼克斯公司 | 针对肿瘤坏死因子的抗体及其用途 |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| WO2005009464A1 (en) | 2003-07-25 | 2005-02-03 | Lopez De Silanes Juan | Administration of anti-cytokine f(ab')2 antibody fragments |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2005042028A2 (en) | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
| SI2805728T1 (sl) | 2003-12-23 | 2020-07-31 | Genentech, Inc. | Nova protitelesa proti il 13 in uporabe le-teh |
| AU2004308441A1 (en) * | 2003-12-24 | 2005-07-14 | Wyeth | Methods of treating asthma |
| JP2007522246A (ja) | 2004-02-12 | 2007-08-09 | ネクター セラピューティクス | インターロイキン−１３拮抗剤粉末剤、スプレードライ粒子、及び方法 |
| EP1720573A4 (en) * | 2004-02-27 | 2008-04-02 | Centocor Inc | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH IL-13 |
| US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| US20070048785A1 (en) * | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| AR049390A1 (es) * | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| CA2672215A1 (en) | 2006-12-11 | 2008-06-19 | Wyeth | Methods and compositions for treating and monitoring treatment of il-13-associated disorders |
| RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
-
2005
- 2005-06-08 AR ARP050102343A patent/AR049390A1/es active IP Right Grant
- 2005-06-09 BR BRPI0510881-0A patent/BRPI0510881A/pt not_active IP Right Cessation
- 2005-06-09 RU RU2006140793/10A patent/RU2427589C2/ru not_active IP Right Cessation
- 2005-06-09 CN CN2005800191385A patent/CN101141980B/zh not_active Expired - Fee Related
- 2005-06-09 MX MXPA06014299A patent/MXPA06014299A/es active IP Right Grant
- 2005-06-09 BR BRPI0511910-3A patent/BRPI0511910A/pt not_active IP Right Cessation
- 2005-06-09 US US11/149,309 patent/US7615213B2/en not_active Expired - Fee Related
- 2005-06-09 CN CN2012102800731A patent/CN102827280A/zh active Pending
- 2005-06-09 JP JP2007527730A patent/JP2008515776A/ja not_active Withdrawn
- 2005-06-09 TW TW094119110A patent/TWI391133B/zh active
- 2005-06-09 AU AU2005252700A patent/AU2005252700A1/en not_active Withdrawn
- 2005-06-09 AU AU2005253981A patent/AU2005253981B2/en not_active Ceased
- 2005-06-09 CA CA002567081A patent/CA2567081A1/en not_active Abandoned
- 2005-06-09 EP EP05786816A patent/EP1756161A2/en not_active Withdrawn
- 2005-06-09 CA CA002567129A patent/CA2567129A1/en not_active Abandoned
- 2005-06-09 WO PCT/US2005/020334 patent/WO2005121177A2/en active Application Filing
- 2005-06-09 MX MXPA06014298A patent/MXPA06014298A/es unknown
- 2005-06-09 SG SG200905834-8A patent/SG155260A1/en unknown
- 2005-06-09 SG SG200706331-6A patent/SG135207A1/en unknown
- 2005-06-09 NZ NZ582046A patent/NZ582046A/en not_active IP Right Cessation
- 2005-06-09 KR KR1020137008282A patent/KR101462878B1/ko not_active IP Right Cessation
- 2005-06-09 KR KR1020067025990A patent/KR101299073B1/ko not_active IP Right Cessation
- 2005-06-09 EP EP05786668A patent/EP1765401A4/en not_active Withdrawn
- 2005-06-09 WO PCT/US2005/020160 patent/WO2005123126A2/en active Application Filing
- 2005-06-09 KR KR1020067025945A patent/KR20070034487A/ko not_active Application Discontinuation
- 2005-06-09 JP JP2007527694A patent/JP4970258B2/ja not_active Expired - Fee Related
- 2005-06-09 EP EP12169663A patent/EP2548889A1/en not_active Withdrawn
- 2005-06-09 RU RU2006140096/13A patent/RU2006140096A/ru not_active Application Discontinuation
-
2006
- 2006-11-07 IL IL179093A patent/IL179093A0/en unknown
- 2006-11-22 IL IL179476A patent/IL179476A/en not_active IP Right Cessation
- 2006-12-05 CR CR8784A patent/CR8784A/es not_active Application Discontinuation
- 2006-12-05 CR CR8783A patent/CR8783A/es not_active Application Discontinuation
- 2006-12-11 EC EC2006007072A patent/ECSP067072A/es unknown
- 2006-12-11 EC EC2006007073A patent/ECSP067073A/es unknown
-
2007
- 2007-01-05 NO NO20070087A patent/NO20070087L/no not_active Application Discontinuation
- 2007-01-08 NO NO20070133A patent/NO20070133L/no unknown
-
2009
- 2009-10-08 US US12/575,896 patent/US8221752B2/en not_active Expired - Fee Related
-
2010
- 2010-08-17 AR ARP100103010A patent/AR077931A2/es unknown
-
2011
- 2011-03-09 JP JP2011051866A patent/JP2011155980A/ja active Pending
-
2014
- 2014-08-20 JP JP2014167064A patent/JP2015037401A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077931A2 (es) | Anticuerpos contra la interleuquina-13 humana y usos de los mismos | |
| Tan et al. | Venom-gland transcriptome and venom proteome of the Malaysian king cobra (Ophiophagus hannah) | |
| BRPI0606368A2 (pt) | anticorpos contra receptor alfa1 de il-13, usos dos mesmos, composição farmacêitica, e método para fabricação da mesma, célula hospedeira recombinante, ácido nucléico, vetor de expressão, método para a produção de um polipeptìdeo , bem como linhagem celular de hibridoma | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| JP2019038834A (ja) | 分泌様免疫グロブリンを含む組成物 | |
| BR112012007821A2 (pt) | polipeptídeos para ligação ao "receptor de produtos finais de glicação avançada" bem como composições e métodos envolvendo os mesmos | |
| US8663950B2 (en) | Production of a monoclonal antibody therapeutic against west nile virus in plants | |
| CN102471765A (zh) | 显示出缩短的生物学活性的神经毒素 | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| CA2969635C (en) | Method for the treatment of idiopathic pulmonary fibrosis | |
| CA2704119C (en) | Humanized anti-venezuelan equine encephalitis virus recombinant antibodies | |
| UA98620C2 (uk) | Атенуйований вірус класичної лихоманки свиней, що містить модифікований глікопротеїн е2 | |
| EP3805255A1 (en) | Acinetobacter baumannii immunogenic protein and composition and application thereof | |
| TW201522379A (zh) | Ｃｈｒｄｌ－１抗原結合蛋白及治療方法 | |
| US20180237502A1 (en) | Pan-ebola and pan-filovirus protective epitopes, antibodies, and antibody cocktails | |
| KR20160119806A (ko) | 신규한 온전한 범위의 항-뎅기 항체 | |
| Liu et al. | Purification and characterization of parvalbumins from silver carp (Hypophthalmichthy molitrix) | |
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| DE69840105D1 (de) | Plättchen-spezifische antigene und deren pharmazeutische verwendung | |
| US11505619B2 (en) | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease | |
| JP2019503341A (ja) | 植物細胞に生物学的に封入された、治療用タンパク質の、疾患の治療のための関心のある細胞型への標的化された送達 | |
| WO2017156423A2 (en) | Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever | |
| RU2016117140A (ru) | Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы | |
| Abe et al. | The presence of the 50-kDa subunit of dynactin complex in the nerve growth cone | |
| TWI769150B (zh) | 糖尿病之治療、類鐸受體第四型調節劑及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |